2. Search Result
Search Result
Results for "

dihydropyrimidine

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

1

Natural
Products

2

Isotope-Labeled Compounds

1

Antibodies

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W012926
    Dihydrouracil

    5,6-Dihydrouracil

    		 Endogenous Metabolite Metabolic Disease
    Dihydrouracil (5,6-Dihydrouracil), a metabolite of Uracil, can be used as a marker for identification of dihydropyrimidine dehydrogenase (DPD)-deficient .
    Dihydrouracil
  • HY-124062
    TAS-114
    2 Publications Verification

    		 Others Cancer
    TAS-114 is an orally active dual dUTPase/dihydropyrimidine dehydrogenase (DPD) inhibitor, can improving the therapeutic efficacy of fluoropyrimidine .
    TAS-114
  • HY-17469
    Gimeracil
    2 Publications Verification

    Gimestat

    		 Others Cancer
    Gimeracil, a component of an oral fluoropyrimidine derivative S-1, inhibits DNA DSB repair and is a potent inhibitor of DPYD (dihydropyrimidine dehydrogenase, DPD) .
    Gimeracil
  • HY-162623
    EGFR/HER2-IN-15

    		EGFR Cancer
    EGFR/HER2-IN-15, a dihydropyrimidine, is a potent EGFR/HER2 inhibitor. EGFR/HER2-IN-15 significantly inhibits EGFR wt activity with an IC50 of 37.21 nM. EGFR/HER2-IN-15 has anticaner effects .
    EGFR/HER2-IN-15
  • HY-132888
    NCATS-SM4487

    		Others Metabolic Disease
    NCATS-SM4487 is a highly selective unique dihydropyrimidine inhibitor against GALK1, with an IC50 value of 0.05 μM.
    NCATS-SM4487
  • HY-W012926S1
    Dihydrouracil-d4

    5,6-Dihydrouracil-d4

    		 Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    Dihydrouracil-d4 is the deuterium labeled Dihydrouracil . Dihydrouracil (HY-W012926), a metabolite of Uracil, can be used as a marker for identification of dihydropyrimidine dehydrogenase (DPD)-deficient .
    Dihydrouracil-d4
  • HY-W012926S
    Dihydrouracil-13C4,15N2

    5,6-Dihydrouracil-13C4,15N2

    		 Endogenous Metabolite Metabolic Disease
    Dihydrouracil- 13C4, 15N2 is the 13C and 15N labeled Dihydrouracil[1]. Dihydrouracil (5,6-Dihydrouracil), a metabolite of Uracil, can be used as a marker for identification of dihydropyrimidine dehydrogenase (DPD)-deficient[2][3].
    Dihydrouracil-13C4,15N2
  • HY-162788
    EGFR-IN-121

    		EGFR Cancer
    EGFR-IN-121 (compound 15) is a EGFR and VEGFR-2 dual inhibitor with IC50s of 84 and 3.5 nM, respectively .
    EGFR-IN-121
  • HY-W454906
    tDHU, acid

    		Ligands for E3 Ligase Autophagy Apoptosis Cancer
    tDHU, acid is a dihydropyrimidinecereblon ligand that contains an E3 ligase ligand and a benzoic acid linker. tDHU, acid can be used as an E3 ubiquitin ligase ligand-Linker conjugate for the development of PROTACs .
    tDHU, acid
  • HY-124178
    (R)-Levrazoxane

    (R)-ICRF 186

    		 Others Metabolic Disease
    (R)-Levrazoxane ((R)-ICRF 186) is enzymatically hydrolysed to one-ring open intermediates by dihydropyrimidine amidohydrolase (DPHase), which is present in the liver and kidney. The radiosensitizing efficiency of (R)-Levrazoxane towards EMT6 mouse mammary tumour cells is greater than that of Dexrazoxane (HY-B0581). (R)-Levrazoxane is promising for research of liver and kidney related diseases .
    (R)-Levrazoxane
  • HY-138820
    SW02

    		HSP Neurological Disease
    SW02 is a potent activator of ATPase activity of Hsp70, with an EC50 of 150 μM. SW02 leads to accumulation of both total tau and phosphorylated tau (pTau) .
    SW02
  • HY-W014109
    (E)-5-(2-Bromovinyl)pyrimidine-2,4(1H,3H)-dione

    (E)-5-(2-Bromovinyl)uracil; BVU

    		 Others Infection
    (E)-5-(2-Bromovinyl)uracil (BVU) is a pyrimidine base and an inactive metabolite of the antiviral agents sorivudine and (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) that may be regenerated to BVDU in vivo. BVU irreversibly inactivates dihydropyrimidine dehydrogenase (DPD) in an NADPH-dependent manner. It enhances the efficacy of the chemotherapeutic agent and DPD substrate 5-fluorouracil (HY-90006) in a P388 murine leukemia model when administered at a dose of 200 μmol/kg, increasing survival time.
    (E)-5-(2-Bromovinyl)pyrimidine-2,4(1H,3H)-dione
  • HY-134160
    5,6-Dihydro-5-Fluorouracil

    5-DHFU; 5-Fluorodihydropyrimidine-2,4-dione; 5-Fluorodihydrouracil

    		 Others Cancer
    5,6-Dihydro-5-Fluorouracil (5-DHFU; 5-Fluorodihydropyrimidine-2,4-dione) is the active metabolite of the thymidylate synthase inhibitor prodrug 5-fluorouracil (HY-90006), which is formed from 5-fluorouracil by dihydropyrimidine dehydrogenase (DPD). 5,6-Dihydro-5-Fluorouracil is cytotoxic to HaCaT keratinocytes (IC50=13.5 μM). Intravenous administration of 5,6-Dihydro-5-Fluorouracil (90 mg/kg/wk) in combination with 5-fluorouracil and the DPD inhibitor eniluracil (HY-10533) slows tumor growth in a rat colon cancer model.
    5,6-Dihydro-5-Fluorouracil
  • HY-118046
    GSK2163632A

    		G Protein-coupled Receptor Kinase (GRK) Cardiovascular Disease
    GSK2163632A is a selective G protein-coupled receptor kinase (GRK) inhibitor that may serve as a probe for studying heart failure and Parkinson's disease. Screening of known protein kinase inhibitors by differential scanning fluorescence method revealed that the melting points of GRK2 and GRK5 increased. Enzymatic assays of the 14 most stable hits revealed that three exhibited nanomolar inhibitory potency against a single GRK, with some showing significant selectivity. Most of the identified compounds can be divided into two categories: indazole/dihydropyrimidine compounds selectively inhibit GRK2, and pyrrolopyrimidine compounds effectively inhibit GRK1 and GRK5 but with modest selectivity. The two most inhibitory representative compounds, GSK180736A and GSK2163632A, are co-crystals with GRK2 and GRK1, respectively, and their atomic structures were determined to 2.6 and 1.85 ? distances, respectively. GSK180736A, as an inhibitor of Rho-related coiled-coil protein kinase, binds to GRK2 in a manner similar to paroxetine, while GSK2163632A, as an inhibitor of insulin-like growth factor 1 receptor, occupies a novel region of the GRK active site cleft and may be used to achieve more Selectivity. However, both compounds inhibited GRK no more potently than their original targets. These data provide a basis for the rational design of more effective and selective GRK inhibitors in the future .
    GSK2163632A

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: